JW THERAP-B (02126) surged over 10% in afternoon trading. As of press time, the stock was up 8.42% to HK$5.41, with trading volume reaching HK$26.336 million.

On the news front, JW THERAP-B recently released its interim results, reporting revenue of RMB106 million for the first half of the year, up 22.5% year-on-year. Gross profit reached RMB65.117 million, increasing 48.86% year-on-year, while R&D expenses totaled RMB92.041 million.

CICC pointed out that the company achieved significant reduction in operating losses in the first half, primarily driven by cost reduction and expense control, as well as licensing collaboration agreements. The firm expects the loss reduction trend to continue throughout the full year.

According to company announcements, JW THERAP-B initiated IIT studies for JWCAR201 in hematologic malignancies and autoimmune diseases in the second half of 2024, with patient enrollment currently underway. The company holds global rights to this product, and through dual targeting approach, believes the product has potential for broader efficacy and higher signal threshold.

Based on company disclosures, encouraging preliminary data has been obtained for hematologic malignancies, with plans to present IIT data at the American Society of Hematology Annual Meeting in December 2025. Additionally, the market awaits updates on CD19 CAR-T data for systemic lupus erythematosus (SLE).